VANDERBILT UNIVERSITY MEDICAL CENTER
The Sunshine Act requires manufacturers to report payments to teaching hospitals as institutions, separately from payments to individual physicians. These figures are money reported to the hospital itself — most of it research funding and grants, not compensation to any named doctor.
- Total reported
- $228.2M
- Transactions
- 24,963
- Companies
- 40
- Average per transaction
- $9,143
Who reported the payments
| Merck | $20,849,055 |
| Amgen | $17,474,654 |
| Takeda Pharmaceuticals U.S.A., Inc. | $11,249,977 |
| AstraZeneca | $11,002,897 |
| Incyte Corporation | $9,885,125 |
| Pfizer | $9,527,488 |
| AbbVie | $9,082,751 |
| Genentech, Inc. | $7,981,363 |
| Gilead | $7,060,209 |
| GE HealthCare | $6,512,849 |
| Medtronic | $6,466,297 |
| Edwards Lifesciences | $5,612,661 |
| E.r. Squibb & Sons, L.L.C. | $4,732,150 |
| Janssen Research & Development, LLC | $4,517,173 |
| Ultragenyx Pharmaceutical Inc. | $3,797,829 |
| CSL Behring | $3,762,832 |
| Boehringer Ingelheim | $3,692,452 |
| Boehringer Ingelheim International GmbH | $3,008,754 |
| Alnylam Pharmaceuticals Inc. | $2,953,726 |
| Abbott | $2,533,212 |
| Boston Scientific | $2,314,794 |
| Eli Lilly | $2,201,602 |
| Siemens Medical Solutions USA, Inc. | $2,178,539 |
| Novo Nordisk AS | $2,125,275 |
| Biomarin Pharmaceutical Inc. | $1,707,973 |
| Acadia Pharmaceuticals Inc | $1,635,426 |
| Regeneron | $1,629,474 |
| Rhythm Pharmaceuticals, Inc. | $1,528,737 |
| Bayer | $1,512,130 |
| Teva Pharmaceuticals USA, Inc. | $1,506,347 |
| Eisai Inc. | $1,498,801 |
| Roche TCRC, Inc. | $1,352,081 |
| EMD Serono, Inc. | $1,313,778 |
| Shire North American Group Inc | $1,285,258 |
| Kadmon Corporation LLC | $1,256,461 |
| Taiho Oncology, Inc. | $1,242,387 |
| Exelixis Inc. | $1,240,343 |
| Biogen | $1,203,468 |
| Jazz Pharmaceuticals Inc. | $1,146,318 |
| Astellas Pharma Inc | $1,110,554 |